Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: Factors associated with response

M. K. Jain, L. Comanor, A. Clinton White, P. Kipnis, C. Elkin, K. Leung, A. Ocampo, N. Attar, Philip Keiser, W. M. Lee

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT® HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene® HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80%), loss of HBe antigen (HBeAg) (40%) and loss of HBeAg and gain of anti-HBe (20%) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74% (26/35) vs 20% (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95% CI: 2.0-50], previous HIV therapy (OR 6.5; 95% CI: 1.2-35) and <90% compliance (OR 3.7; 95% CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalJournal of Viral Hepatitis
Volume14
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Tenofovir
Lamivudine
Hepatitis B
Hepatitis B virus
HIV
Genotype
Therapeutics
DNA
Odds Ratio
Compliance
Branched DNA Signal Amplification Assay

Keywords

  • HBV genotype
  • HIV/HBV coinfection
  • Lamivudine
  • Tenofovir
  • Therapeutic response

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients : Factors associated with response. / Jain, M. K.; Comanor, L.; White, A. Clinton; Kipnis, P.; Elkin, C.; Leung, K.; Ocampo, A.; Attar, N.; Keiser, Philip; Lee, W. M.

In: Journal of Viral Hepatitis, Vol. 14, No. 3, 03.2007, p. 176-182.

Research output: Contribution to journalArticle

Jain, M. K. ; Comanor, L. ; White, A. Clinton ; Kipnis, P. ; Elkin, C. ; Leung, K. ; Ocampo, A. ; Attar, N. ; Keiser, Philip ; Lee, W. M. / Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients : Factors associated with response. In: Journal of Viral Hepatitis. 2007 ; Vol. 14, No. 3. pp. 176-182.
@article{db1b5e3784d7421cb9996cfd9804e896,
title = "Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: Factors associated with response",
abstract = "As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT{\circledR} HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene{\circledR} HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80{\%}), loss of HBe antigen (HBeAg) (40{\%}) and loss of HBeAg and gain of anti-HBe (20{\%}) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74{\%} (26/35) vs 20{\%} (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95{\%} CI: 2.0-50], previous HIV therapy (OR 6.5; 95{\%} CI: 1.2-35) and <90{\%} compliance (OR 3.7; 95{\%} CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.",
keywords = "HBV genotype, HIV/HBV coinfection, Lamivudine, Tenofovir, Therapeutic response",
author = "Jain, {M. K.} and L. Comanor and White, {A. Clinton} and P. Kipnis and C. Elkin and K. Leung and A. Ocampo and N. Attar and Philip Keiser and Lee, {W. M.}",
year = "2007",
month = "3",
doi = "10.1111/j.1365-2893.2006.00797.x",
language = "English (US)",
volume = "14",
pages = "176--182",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients

T2 - Factors associated with response

AU - Jain, M. K.

AU - Comanor, L.

AU - White, A. Clinton

AU - Kipnis, P.

AU - Elkin, C.

AU - Leung, K.

AU - Ocampo, A.

AU - Attar, N.

AU - Keiser, Philip

AU - Lee, W. M.

PY - 2007/3

Y1 - 2007/3

N2 - As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT® HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene® HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80%), loss of HBe antigen (HBeAg) (40%) and loss of HBeAg and gain of anti-HBe (20%) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74% (26/35) vs 20% (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95% CI: 2.0-50], previous HIV therapy (OR 6.5; 95% CI: 1.2-35) and <90% compliance (OR 3.7; 95% CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.

AB - As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT® HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene® HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80%), loss of HBe antigen (HBeAg) (40%) and loss of HBeAg and gain of anti-HBe (20%) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74% (26/35) vs 20% (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95% CI: 2.0-50], previous HIV therapy (OR 6.5; 95% CI: 1.2-35) and <90% compliance (OR 3.7; 95% CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.

KW - HBV genotype

KW - HIV/HBV coinfection

KW - Lamivudine

KW - Tenofovir

KW - Therapeutic response

UR - http://www.scopus.com/inward/record.url?scp=33846997179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846997179&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2006.00797.x

DO - 10.1111/j.1365-2893.2006.00797.x

M3 - Article

C2 - 17305883

AN - SCOPUS:33846997179

VL - 14

SP - 176

EP - 182

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 3

ER -